Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL)

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL)

Purpose Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point assessed post-treatment would expedite clinical trial conduct and accelerate patient...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Qian Shi, Norbert Schmitz, Fang‐Shu Ou, Jesse G. Dixon, David Cunningham, Michael Pfreundschuh, John F. Seymour, Ulrich Jaeger, Thomas M. Habermann, Corinne Haïoun, Hervé Tilly, Hervé Ghesquières, Francesco Merli, Marita Ziepert, Raoul Herbrecht, Jocelyne Flament, Tommy Fu, Bertrand Coiffier, Christopher R. Flowers
Médium: Artigo
Jazyk:angličtina
Vydáno: 2018
On-line přístup:https://doi.org/10.1200/jco.2018.77.9124
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1200/jco.2018.77.9124

Podobné jednotky